Table 1 Sociodemographic and clinical data by follow-up care models

Age, mean (SD)

50 (12.9)

45 (14.5)

<.001(t-test)

Age categories n (%)

 18-39

31 (22)

58 (35)

0.012 (χ²)

 40-80

109 (78)

106 (65)

Sex n (%)

 Male

63 (45)

67 (41)

 Female

77 (55)

97 (59)

ns

Current smoker n (%)

50 (37)

61 (38)

ns

Education level n (%)

 Compulsory school only

12 (9)

22 (13)

 Upper secondary school

50 (36)

69 (42)

ns

 Higher education < 4 years

34 (24)

42 (26)

 Higher education ≥ 4 years

44 (31)

31 (19)

Disease duration, years mean (SD)

14.8 (10.1)

10.7 (8.2)

<.001 (t-test)

IBD classification ^a n (%)

 UC extent

n = 92 (59)

n = 65 (41)

  E1 ulcerative proctitis

20 (21)

6 (9)

ns

  E2 left-sided UC

39 (42)

29 (45)

ns

  E3 extensive UC

33 (36)

30 (46)

ns

 CD localization

n = 48

n = 98

  L1 ileal

24 (50)

43 (44)

ns

  L2 colonic

11 (23)

17 (17)

ns

  L3 ileocolonic

13 (27)

38 (39)

ns

  L4 isolated upper disease^b

none

none

 CD behavior

  B1 non-stricturing, non-penetrating

47 (98)

81 (83)

ns

  B2 stricturing

19 (40)

39 (40)

ns

  B3 penetrating

13 (27)

17 (17)

ns

  P perianal disease modifier

5 (10)

5 (5)

Medication at inclusion n (%)

 Aminosalicylic acid (5-ASA)

82 (59)

69 (42)

<0.001(χ²)

 Azathioprine (AZA)/Methotrexate (MTX)

27 (19)

29 (18)

ns

 Biological^c

18 (13)

48 (29)

<0.001(χ²)

 Prednisolone^d

18 (13)

23 (14)

ns